Clinical trial
Tarceva and Capecitabine for Pancreatic Cancer
NCT00125021 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00125021 |
|---|---|
| Title | Tarceva and Capecitabine for Pancreatic Cancer |
| Official title | A Phase II Study of OSI-774 (Tarceva) in Combination With Capecitabine in Previously Treated Patients With Metastatic Pancreatic Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Genentech, Inc. Industry Roche Global Development Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Capecitabine, OSI-774 |
| Enrollment | 32 |
| Start date | Oct 1, 2003 |
| Primary completion | Jun 1, 2004 |
| Completion | Sep 1, 2008 |
| First posted | Jul 29, 2005 |
| Last update posted | Nov 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: